Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2026ESMO OpenOpen Access

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape

View Full Paper
Ask AI
Bookmark
Share

Authors

FGF. GayGBG. BudaMPM.T. Petrucci

Discussion

Loading...

Member takes

Overview

This review highlights selinexor's effectiveness in relapsed/refractory multiple myeloma, suggesting new treatment strategies for challenging patient groups.

Key Points

  • To evaluate the role of selinexor in the treatment of multiple myeloma, especially in high-risk and difficult-to-treat subgroups.
  • Overview of selinexor's mechanism of action and its use in combination therapies.
  • Discussion of clinical results from selinexor-based treatments in various patient populations.
  • Evaluation of potential strategies for improving treatment outcomes and adherence.
  • Selinexor demonstrated encouraging results in combination with other therapies for relapsed/refractory MM.
  • Efficacy noted across different subgroups, including triple-class refractory disease and renal dysfunction.
  • Continued need for research on selinexor combinations to address unmet clinical needs.

Cite This Study

Gay et al. (2026) studied this question.

synapsesocial.com/papers/69b64ccdb42794e3e660dfbfhttps://doi.org/10.1016/j.esmoop.2025.106054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[The Application Progress of Selinexor in the Treatment of Relapsed and Refractory Multiple Myeloma--Review].2025
  2. 2Selinexor potentiates NK cell activation against multiple myeloma2026
  3. 3Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series2024 · 1 citations
  4. 4Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy2025
  5. 5Navigating the Post‐ <scp>BCMA</scp> / <scp>GPRC5D</scp> Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis2026 · 2 citations